Giuliana Muzio

Prof. Giuliana Muzio

Universita degli Studi di Torino, Department of Clinical and Biological Sciences, Torino, Italy
orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2012 in Free Radical Biology and Medicine
Verified
Journal Article
Open access
Giuliana MuzioGiuliana Muzio
Giuliana Muzio
MMM. Maggiora
M. Maggiora
EPE. Paiuzzi
E. Paiuzzi
MOM. Oraldi
M. Oraldi
RCR.A. Canuto
R.A. Canuto
Aldehyde dehydrogenases (ALDHs) oxidize aldehydes to the corresponding carboxylic acids using either NAD or NADP as a coenzyme. Aldehydes are highly reactive aliphatic or aromatic molecules that play an important role in numerous physiological, pathological, and pharmacological processes. ALDHs have been discovered in practically all organisms and there are multiple isoforms, with multiple subcellular localizations. More than 160 ALDH cDNAs or genes have been isolated and sequenced to date from various sources, including bacteria, yeast, fungi, plants, and animals. The eukaryote ALDH genes can be subdivided into several families; the human genome contains 19 known ALDH genes, as well as many pseudogenes. Noteworthy is the fact that elevated activity of various ALDHs, namely ALDH1A2, ALDH1A3, ALDH1A7, ALDH2*2, ALDH3A1, ALDH4A1, ALDH5A1, ALDH6, and ALDH9A1, has been observed in normal and cancer stem cells. Consequently, ALDHs not only may be considered markers of these cells, but also may well play a functional role in terms of self-protection, differentiation, and/or expansion of stem cell populations. The ALDH3 family includes enzymes able to oxidize medium-chain aliphatic and aromatic aldehydes, such as peroxidic and fatty aldehydes. Moreover, these enzymes also have noncatalytic functions, including antioxidant functions and some structural roles. The gene of the cytosolic form, ALDH3A1, is localized on chromosome 17 in human beings and on the 11th and 10th chromosome in the mouse and rat, respectively. ALDH3A1 belongs to the phase II group of drug-metabolizing enzymes and is highly expressed in the stomach, lung, keratinocytes, and cornea, but poorly, if at all, in normal liver. Cytosolic ALDH3 is induced by polycyclic aromatic hydrocarbons or chlorinated compounds, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin, in rat liver cells and increases during carcinogenesis. It has been observed that this increased activity is directly correlated with the degree of deviation in hepatoma and lung cancer cell lines, as is the case in chemically induced hepatoma in rats. High ALDH3A1 expression and activity have been correlated with cell proliferation, resistance against aldehydes derived from lipid peroxidation, and resistance against drug toxicity, such as oxazaphosphorines. Indeed, cells with a high ALDH3A1 content are more resistant to the cytostatic and cytotoxic effects of lipidic aldehydes than are those with a low content. A reduction in cell proliferation can be observed when the enzyme is directly inhibited by the administration of synthetic specific inhibitors, antisense oligonucleotides, or siRNA or indirectly inhibited by the induction of peroxisome proliferator-activated receptor γ (PPARγ) with polyunsaturated fatty acids or PPARγ transfection. Conversely, cell proliferation is stimulated by the activation of ALDH3A1, whether by inhibiting PPARγ with a specific antagonist, antisense oligonucleotides, siRNA, or a medical device (i.e., composite polypropylene prosthesis for hernia repair) used to induce cell proliferation. To date, the mechanisms underlying the effects of ALDHs on cell proliferation are not yet fully clear. A likely hypothesis is that the regulatory effect is mediated by the catabolism of some endogenous substrates deriving from normal cell metabolism, such as 4-hydroxynonenal, which have the capacity to either stimulate or inhibit the expression of genes involved in regulating proliferation.

1 March 2007 in Acta Biomaterialia
Verified
Journal Article
Closed access
Chiara Vitale-BrovaroneChiara Vitale-Brovarone
Chiara Vitale-Brovarone
EVEnrica Vernè
Enrica Vernè
LRL. Robiglio
L. Robiglio
PAP. Appendino
P. Appendino
FBF. Bassi
F. Bassi
RCR. Canuto
R. Canuto

1 April 2007 in Journal of Periodontology
Verified
Journal Article
Closed access
GPGiulio Preti
Giulio Preti
GMGermana Martinasso
Germana Martinasso
BPBruno Peirone
Bruno Peirone
RNRoberto Navone
Roberto Navone
CMCarlo Manzella
Carlo Manzella
Gianmario SchieranoGianmario Schierano
Gianmario Schierano
Background: Most dental implants are positioned using a drilling surgery technique. However, dentistry recently experienced the implementation of piezoelectric surgery. This technique was introduced to overcome some of the limitations involving rotating instruments in bone surgery. This study used biomolecular and histologic analyses to compare the osseointegration of porous implants positioned using traditional drills versus the piezoelectric bone surgery technique.Methods: Porous titanium implants were inserted into minipig tibias. Histomorphology and levels of bone morphogenetic protein (BMP)‐4, transforming growth factor (TGF)‐β2, tumor necrosis factor‐alpha, and interleukin‐1β and ‐10 were evaluated in the peri‐implant osseous samples.Results: Histomorphological analyses demonstrated that more inflammatory cells were present in samples from drilled sites. Also, neo‐osteogenesis was consistently more active in bone samples from the implant sites that were prepared using piezoelectric bone surgery. Moreover, bone around the implants treated with the piezoelectric bone surgery technique showed an earlier increase in BMP‐4 and TGF‐β2 proteins as well as a reduction in proinflammatory cytokines.Conclusion: Piezoelectric bone surgery appears to be more efficient in the first phases of bone healing; it induced an earlier increase in BMPs, controlled the inflammatory process better, and stimulated bone remodeling as early as 56 days post‐treatment.

1 May 2014 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Marta MiolaMarta Miola
Marta Miola
CBChiara Vitale Brovarone
Chiara Vitale Brovarone
GMGiovanni Maina
Giovanni Maina
FRFederica Rossi
Federica Rossi
LBLoredana Bergandi
Loredana Bergandi
EVEnrica Vernè
Enrica Vernè

1 November 2011 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
CTC. Tonda-Turo
C. Tonda-Turo
PGPiergiorgio Gentile
Piergiorgio Gentile
SSS. Saracino
S. Saracino
VCV. Chiono
V. Chiono
VNV.K. Nandagiri
V.K. Nandagiri
Gianluca CiardelliGianluca Ciardelli
Gianluca Ciardelli

25 November 2011 in British Journal of Nutrition
Verified
Journal Article
Closed access
CFConcetta Finocchiaro
Concetta Finocchiaro
OSOlivia Segre
Olivia Segre
MFMaurizio Fadda
Maurizio Fadda
TMTaira Monge
Taira Monge
MSMara Scigliano
Mara Scigliano
RCRosa A. Canuto
Rosa A. Canuto
PUFA from fish oil appear to have anti-inflammatory and anti-oxidative effects and improve nutritional status in cancer patients. With this as background, the aim of the present study was to investigate the effect of EPA plus DHA on inflammatory condition, and oxidative and nutritional status in patients with lung cancer. In our multicentre, randomised, double-blind trial, thirty-three patients with a diagnosis of advanced inoperable non-small-cell lung cancer and undergoing chemotherapy were divided into two groups, receiving four capsules/d containing 510 mg of EPA and 340 mg of DHA, or 850 mg of placebo, for 66 d. At the start of chemotherapy (T0), after 8 d (T1), 22 d (T2) and 66 d (T3), biochemical (inflammatory and oxidative status parameters) and anthropometric parameters were measured in both groups. A significant increase of body weight in the n-3 group at T3v. T0 was observed. Concerning inflammation, C-reactive protein and IL-6 levels differed significantly between the n-3 and placebo groups at T3, and progressively decreased during chemotherapy in the n-3 group, evidencing n-3 PUFA anti-inflammatory action. Concerning oxidative status, plasma reactive oxygen species levels increased in the placebo group v. the n-3 group at the later treatment times. Hydroxynonenal levels increased in the placebo group during the study, while they stabilised in the n-3 group. Our data confirm that the continual assumption of EPA plus DHA determined an anti-inflammatory and anti-oxidative action which could be considered a preliminary goal in anti-cachectic therapy.